{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:56:59Z","timestamp":1767142619389,"version":"build-2238731810"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-024-03098-z","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T03:39:21Z","timestamp":1738726761000},"page":"1360-1392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Na\u00efve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Piotr","family":"Wiland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Both","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman B.","family":"Gaylis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"von Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"3098_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009","volume":"52","author":"TK Kvien","year":"2022","unstructured":"Kvien TK, Patel K, Strand V. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. Semin Arthritis Rheum. 2022;52: 151939. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.009.","journal-title":"Semin Arthritis Rheum"},{"key":"3098_CR2","unstructured":"European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed 14 Dec 2023."},{"key":"3098_CR3","unstructured":"US Food and Drug Administration. Questions and answers on biosimilar development and the BPCI act: GUIDANCE for industry. 2021. https:\/\/www.fda.gov\/media\/119258\/download. Accessed 14 Dec 2023."},{"key":"3098_CR4","unstructured":"World Health Organization. Guidelines on evaluation of similar biological products. 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/ecbs\/who-sbps_22-april-2021.pdf?sfvrsn=f283c924_5. Accessed 14 Dec 2023."},{"issue":"9","key":"3098_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrd1182","volume":"2","author":"B Bain","year":"2003","unstructured":"Bain B, Brazil M. Adalimumab. Nat Rev Drug Discov. 2003;2(9):693\u20134. https:\/\/doi.org\/10.1038\/nrd1182.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3098_CR6","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.xphs.2021.02.003","volume":"110","author":"J Coghlan","year":"2021","unstructured":"Coghlan J, He H, Schwendeman AS. Overview of Humira\u00ae biosimilars: current European landscape and future implications. J Pharm Sci. 2021;110(4):1572\u201382. https:\/\/doi.org\/10.1016\/j.xphs.2021.02.003.","journal-title":"J Pharm Sci"},{"issue":"7","key":"3098_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/apt.17675","volume":"58","author":"\u00c5H Everhov","year":"2023","unstructured":"Everhov \u00c5H, S\u00f6derling J, Befrits G, et al. Increasing healthcare costs in inflammatory bowel disease 2007\u20132020 in Sweden. Aliment Pharmacol Ther. 2023;58(7):692\u2013703. https:\/\/doi.org\/10.1111\/apt.17675.","journal-title":"Aliment Pharmacol Ther"},{"key":"3098_CR8","unstructured":"European Medicines Agency. Summary of product characteristics: Humira. 2009. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/humira-epar-product-information_en.pdf. Accessed 14 Dec 2023."},{"key":"3098_CR9","unstructured":"European Medicines Agency. Summary of product characteristics: Hyrimoz. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hyrimoz-epar-product-information_en.pdf. Accessed 14 Dec 2023."},{"key":"3098_CR10","unstructured":"US Food and Drug Administration. HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761071s015lbl.pdf. Accessed 14 Dec 2023."},{"key":"3098_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14712598.2022.2117546","volume":"23","author":"O von Richter","year":"2023","unstructured":"von Richter O, O\u2019Reilly T, Guerrieri D, et al. GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar. Expert Opin Biol Ther. 2023;23:749\u201358. https:\/\/doi.org\/10.1080\/14712598.2022.2117546.","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"3098_CR12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2021-219951","volume":"80","author":"H Nabi","year":"2021","unstructured":"Nabi H, Georgiadis S, Loft AG, et al. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial. Ann Rheum Dis. 2021;80(11):1400\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219951.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"3098_CR13","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","volume":"61","author":"D Di Giuseppe","year":"2022","unstructured":"Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2022;61(9):3596\u2013605. https:\/\/doi.org\/10.1093\/rheumatology\/keab933.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"3098_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/biologics2040017","volume":"2","author":"L Puig","year":"2022","unstructured":"Puig L, Shams K, Furlan F, et al. Real-world effectiveness and safety of SDZ-ADL (adalimumab biosimilar) in patients with psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Biologics. 2022;2(4):213\u201325. https:\/\/doi.org\/10.3390\/biologics2040017.","journal-title":"Biologics"},{"issue":"3","key":"3098_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour JP, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331. https:\/\/doi.org\/10.1111\/bjd.16890.","journal-title":"Br J Dermatol"},{"issue":"2","key":"3098_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40259-021-00470-1","volume":"35","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Leonardi CL, Gaylis N, et al. Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS). BioDrugs. 2021;35(2):229\u201338. https:\/\/doi.org\/10.1007\/s40259-021-00470-1.","journal-title":"BioDrugs"},{"issue":"6","key":"3098_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","volume":"34","author":"P Wiland","year":"2020","unstructured":"Wiland P, Jeka S, Dokoupilov\u00e1 E, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized, double-blind ADMYRA study. BioDrugs. 2020;34(6):809\u201323. https:\/\/doi.org\/10.1007\/s40259-020-00447-6.","journal-title":"BioDrugs"},{"issue":"suppl 9","key":"3098_CR18","first-page":"L15","volume":"74","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, \u00d8stergaard M, Poddubnyy D, et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):L15.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3098_CR19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/14712598.2019.1603959","volume":"19","author":"O von Richter","year":"2019","unstructured":"von Richter O, Lemke L, Haliduola H, et al. Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. Expert Opinion Biol Ther. 2019;19(10):1057\u201364. https:\/\/doi.org\/10.1080\/14712598.2019.1603959.","journal-title":"Expert Opinion Biol Ther"},{"issue":"10","key":"3098_CR20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/14712598.2019.1571580","volume":"19","author":"O von Richter","year":"2019","unstructured":"von Richter O, Lemke L, Haliduola H, et al. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opinion Biol Ther. 2019;19(10):1075\u201383. https:\/\/doi.org\/10.1080\/14712598.2019.1571580.","journal-title":"Expert Opinion Biol Ther"},{"issue":"3","key":"3098_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, \u00d8stergaard M, Gensler LS, et al. Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig. 2020;40(3):269\u201378. https:\/\/doi.org\/10.1007\/s40261-020-00886-7.","journal-title":"Clin Drug Investig"},{"issue":"Suppl 1","key":"3098_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/annrheumdis-2023-eular.301","volume":"82","author":"X Baraliakos","year":"2023","unstructured":"Baraliakos X, \u00d8stergaard M, Poddubnyy D, et al. OP0059 Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomised phase IIIB study. Ann Rheum Dis. 2023;82(Suppl 1):38\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.301.","journal-title":"Ann Rheum Dis"},{"key":"3098_CR23","unstructured":"Novartis. Sandoz receives US FDA approval for biosimilar Hyrimoz\u00ae (adalimumab-adaz) high-concentration formulation. 2023. https:\/\/www.novartis.com\/news\/media-releases\/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz-high-concentration-formulation. Accessed 14 Dec 2023."},{"key":"3098_CR24","unstructured":"Novartis. Sandoz receives approval by European Commission for Hyrimoz\u00ae (adalimumab) high-concentration formulation. 2023. https:\/\/www.novartis.com\/news\/media-releases\/sandoz-receives-approval-european-commission-hyrimoz-adalimumab-high-concentration-formulation. Accessed 14 Dec 2023."},{"issue":"3","key":"3098_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/sji.12572","volume":"86","author":"LI Bader","year":"2017","unstructured":"Bader LI, Solberg SM, Kaada SH, et al. Assays for infliximab drug levels and antibodies: a matter of scales and categories. Scand J Immunol. 2017;86(3):165\u201370. https:\/\/doi.org\/10.1111\/sji.12572.","journal-title":"Scand J Immunol"},{"issue":"6","key":"3098_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","volume":"157","author":"N Loft","year":"2021","unstructured":"Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2021.0221.","journal-title":"JAMA Dermatol"},{"issue":"Suppl 1","key":"3098_CR27","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/annrheumdis-2021-eular.1563","volume":"80","author":"M Colaci","year":"2021","unstructured":"Colaci M, Aprile ML, La Rosa A, Di Maggio A, Malatino L. AB0218 non-medical switch from adalimumab originator to the biosimilar GP2017 in patients affected by chronic arthritis. Ann Rheum Dis. 2021;80(Suppl 1):1135. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.1563.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"3098_CR28","doi-asserted-by":"publisher","first-page":"POS0252","DOI":"10.1136\/annrheumdis-2023-eular.1373","volume":"82","author":"I Jyssum","year":"2023","unstructured":"Jyssum I, Gehin JE, Kristianslund E, et al. POS0252 Differences in serum drug levels and anti-drug antibodies in patients with inflammatory arthritis treatment with originator vs biosimilar adalimumab. Ann Rheum Dis. 2023;82(Suppl 1):POS0252. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.1373.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3098_CR29","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.dld.2022.07.004","volume":"54","author":"L Lontai","year":"2022","unstructured":"Lontai L, Gonczi L, Balogh F, et al. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease \u2013 a prospective, multicentre study. Dig Liver Dis. 2022;54(12):1639\u201345. https:\/\/doi.org\/10.1016\/j.dld.2022.07.004.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"3098_CR30","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.3390\/biomedicines10081799","volume":"10","author":"G Mocci","year":"2022","unstructured":"Mocci G, Bodini G, Allegretta L, et al. Adalimumab biosimilar GP2017 versus adalimumab originator in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Biomedicines. 2022;10(8):1799. https:\/\/doi.org\/10.3390\/biomedicines10081799.","journal-title":"Biomedicines"},{"issue":"8","key":"3098_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271299","volume":"17","author":"M Wasserbauer","year":"2022","unstructured":"Wasserbauer M, Hlava S, Drabek J, et al. Adalimumab biosimilars in the therapy of Crohn\u2019s disease and ulcerative colitis: prospective multicentric clinical monitoring. PLoS ONE. 2022;17(8): e0271299. https:\/\/doi.org\/10.1371\/journal.pone.0271299.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"3098_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.661","volume":"16","author":"B Gros","year":"2022","unstructured":"Gros B, Soto Escribano P, Mar\u00edn Pedrosa S, Medina Medina R, Ben\u00edtez JM, Iglesias-Flores E. P534 Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remission. J Crohns Colitis. 2022;16(Suppl 1): i486. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.661.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3098_CR33","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/ibd\/izac092","volume":"29","author":"A Tursi","year":"2023","unstructured":"Tursi A, Mocci G, Allegretta L, et al. Comparison of performances of adalimumab biosimilars SB5, ABP501, GP2017, and MSB11022 in treating patients with inflammatory bowel diseases: a real-life, multicenter, observational study. Inflamm Bowel Dis. 2023;29(3):376\u201383. https:\/\/doi.org\/10.1093\/ibd\/izac092.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"3098_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.15403\/jgld-4608","volume":"31","author":"A Tursi","year":"2022","unstructured":"Tursi A, Mocci G, Cuomo A, et al. Replacement of adalimumab originator to adalimumab biosimilar for a non-medical reason in patients with inflammatory bowel disease: a real-life comparison of adalimumab biosimilars currently available in Italy. J Gastrointest Liver Dis. 2022;31(4):411\u20136. https:\/\/doi.org\/10.15403\/jgld-4608.","journal-title":"J Gastrointest Liver Dis"},{"issue":"Suppl 12","key":"3098_CR35","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.jval.2022.09.758","volume":"25","author":"DKA Alnaqbi","year":"2022","unstructured":"Alnaqbi DKA, Alsennani F, Aloqaili DL, et al. EE516 Budget-impact model of adalimumab-biosimilar Sandoz in the management of autoimmune diseases in the Middle East. Value Health. 2022;25(Suppl 12):S157. https:\/\/doi.org\/10.1016\/j.jval.2022.09.758.","journal-title":"Value Health"},{"issue":"Suppl 1","key":"3098_CR36","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1136\/ejhpharm-2021-eahpconf.6","volume":"28","author":"C Bustos Morell","year":"2021","unstructured":"Bustos Morell C, Gonzalez Puyuelo JM, Monforte Gasque MP, Labrador Andujar N, Provencio Del Olmo M, Lazaro Gallardo EM. 1ISG-025\u2005Budget impact analysis of biosimilar adalimumab versus reference adalimumab. Eur J Hosp Pharm. 2021;28(Suppl 1):A3. https:\/\/doi.org\/10.1136\/ejhpharm-2021-eahpconf.6.","journal-title":"Eur J Hosp Pharm"},{"issue":"10-a","key":"3098_CR37","doi-asserted-by":"publisher","first-page":"M5","DOI":"10.18553\/jmcp.2024.24036.","volume":"29","author":"S Chaplin","year":"2023","unstructured":"Chaplin S, van Stiphout J, Chen A, Li E. M5: budget impact analysis of including biosimilar adalimumab on formulary: a United States payer perspective. J Manag Care Spec Pharm. 2023;29(10-a):M5. https:\/\/doi.org\/10.18553\/jmcp.2024.24036.","journal-title":"J Manag Care Spec Pharm"},{"key":"3098_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/annrheumdis-2023-eular.812","volume":"82","author":"H Nabi","year":"2023","unstructured":"Nabi H, Ibsen R, Ibsen M, Kjellberg J, Hetland ML, Glintborg B. POSO376. Does a mandatory switch from originator adalimumab to biosimilar GP2017 or SB5 lead to increased hospital costs? A DANBIO study of > 1300 patients with inflammatory arthritis. Ann Rheum Dis. 2023;82:441\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.812.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3098_CR39","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. https:\/\/doi.org\/10.1186\/ar2794.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3098_CR40","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/medicina58121851","volume":"58","author":"CC Popescu","year":"2022","unstructured":"Popescu CC, Mogo\u0219an CD, Enache L, Codreanu C. Comparison of efficacy and safety of original and biosimilar adalimumab in active rheumatoid arthritis in a real-world national cohort. Medicina. 2022;58(12):1851. https:\/\/doi.org\/10.3390\/medicina58121851.","journal-title":"Medicina"},{"key":"3098_CR41","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1136\/annrheumdis-2021-eular.1433","volume":"80","author":"G Horneff","year":"2021","unstructured":"Horneff G, Dressler F, Ruhlmann M, Geikowski T, Mrusek S, Klein A. Experience with adalimumab biosimilar use in clinical practice: data from the German Biker-Registry. Ann Rheum Dis. 2021;80:933\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.1433.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3098_CR42","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1080\/14712598.2018.1495193","volume":"18","author":"U Kronthaler","year":"2018","unstructured":"Kronthaler U, Fritsch C, Hainzl O, Seidl A, da Silva A. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications. Expert Opin Biol Ther. 2018;18(8):921\u201330. https:\/\/doi.org\/10.1080\/14712598.2018.1495193.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"3098_CR43","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s13555-017-0198-x","volume":"7","author":"A Menter","year":"2017","unstructured":"Menter A, Tha\u00e7i D, Wu JJ, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7(3):365\u201381. https:\/\/doi.org\/10.1007\/s13555-017-0198-x.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1","key":"3098_CR44","doi-asserted-by":"publisher","first-page":"S032","DOI":"10.1093\/ecco-jcc\/jjx180.041","volume":"12","author":"P Bossuyt","year":"2018","unstructured":"Bossuyt P, Atreya R, Taxonera C, et al. DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: interim results of a non-interventional registry, LEGACY. J Crohns Colitis. 2018;12(Suppl 1):S032. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx180.041.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"3098_CR45","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/ibd\/izz008","volume":"25","author":"EV Loftus","year":"2019","unstructured":"Loftus EV, Reinisch W, Panaccione R, et al. Adalimumab effectiveness up to six years in adalimumab-na\u00efve patients with Crohn\u2019s disease: results of the PYRAMID registry. Inflamm Bowel Dis. 2019;25(9):1522\u201331. https:\/\/doi.org\/10.1093\/ibd\/izz008.","journal-title":"Inflamm Bowel Dis"},{"key":"3098_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.989514","volume":"9","author":"G Larid","year":"2022","unstructured":"Larid G, Baudens G, Dandurand A, et al. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: results of a retrospective French multicenter study. Front Med (Lausanne). 2022;9:989514. https:\/\/doi.org\/10.3389\/fmed.2022.989514.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3098_CR47","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","volume":"78","author":"B Glintborg","year":"2019","unstructured":"Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2019;78(2):192\u2013200. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213474.","journal-title":"Ann Rheum Dis"},{"key":"3098_CR48","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/14712598.2023.2211204","volume":"23","author":"P Sarlos","year":"2023","unstructured":"Sarlos P, Bikar A, Farkas N, et al. Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey. Expert Opin Biol Ther. 2023;23:827\u201332. https:\/\/doi.org\/10.1080\/14712598.2023.2211204.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"3098_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7(1):35\u201364. https:\/\/doi.org\/10.1007\/s40744-019-00190-7.","journal-title":"Rheumatol Ther"},{"key":"3098_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152119","volume":"57","author":"S Gall","year":"2022","unstructured":"Gall S, Kiltz U, Kobylinski T, et al. Patient knowledge about biosimilars and satisfaction with the education provided by rheumatologists or nurse specialists in a biosimilar multiswitch scenario - the perception study. Semin Arthritis Rheum. 2022;57:152119. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152119.","journal-title":"Semin Arthritis Rheum"},{"key":"3098_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.917814","volume":"13","author":"E Allocati","year":"2022","unstructured":"Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: a review of clinical evidence. Front Pharmacol. 2022;13:917814. https:\/\/doi.org\/10.3389\/fphar.2022.917814.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3098_CR52","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"3098_CR53","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/bcp.15101","volume":"88","author":"N Garc\u00eda-Beloso","year":"2022","unstructured":"Garc\u00eda-Beloso N, Altab\u00e1s-Gonz\u00e1lez I, Samart\u00edn-Ucha M, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review. Br J Clin Pharmacol. 2022;88(4):1529\u201350. https:\/\/doi.org\/10.1111\/bcp.15101.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3098_CR54","doi-asserted-by":"publisher","first-page":"13699","DOI":"10.1038\/s41598-023-40222-5","volume":"13","author":"AB de Oliveira","year":"2023","unstructured":"de Oliveira AB, Almeida MO, de Medeiros-Ribeiro AC, de Oliveira Andrade DC, de Oliveira Junior HA, de So\u00e1rez PC. Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis. Sci Rep. 2023;13(1):13699. https:\/\/doi.org\/10.1038\/s41598-023-40222-5.","journal-title":"Sci Rep"},{"issue":"5","key":"3098_CR55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: a systematic review of studies. BioDrugs. 2022;36(5):625\u201337. https:\/\/doi.org\/10.1007\/s40259-022-00546-6.","journal-title":"BioDrugs"},{"key":"3098_CR56","unstructured":"European Medicines Agency and Heads of Medicines Agencies. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed 14 Dec 2023."},{"issue":"4","key":"3098_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40259-022-00538-6","volume":"36","author":"JP Park","year":"2022","unstructured":"Park JP, Jung B, Park HK, et al. Interchangeability for biologics is a legal distinction in the USA, not a clinical one. BioDrugs. 2022;36(4):431\u20136. https:\/\/doi.org\/10.1007\/s40259-022-00538-6.","journal-title":"BioDrugs"},{"key":"3098_CR58","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40259-023-00619-0","volume":"37","author":"HP Cohen","year":"2023","unstructured":"Cohen HP, Turner M, McCabe D, Woollett GR. Future evolution of biosimilar development by application of current science and available evidence: the developer\u2019s perspective. BioDrugs. 2023;37:583\u201393. https:\/\/doi.org\/10.1007\/s40259-023-00619-0.","journal-title":"BioDrugs"},{"key":"3098_CR59","unstructured":"US Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry 2019. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-demonstrating-interchangeability-reference-product-guidance-industry. Accessed 14 Dec 2023."},{"key":"3098_CR60","unstructured":"US Food and Drug Administration. Updated FDA labeling recommendations for biosimilar and interchangeable biosimilar products. 2023. https:\/\/www.fda.gov\/drugs\/our-perspective\/updated-fda-labeling-recommendations-biosimilar-and-interchangeable-biosimilar-products. Accessed 19 Dec 2023."},{"key":"3098_CR61","doi-asserted-by":"publisher","first-page":"1151764","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764. https:\/\/doi.org\/10.3389\/fphar.2023.1151764.","journal-title":"Front Pharmacol"}],"updated-by":[{"DOI":"10.1007\/s12325-025-03181-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03098-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03098-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:16:48Z","timestamp":1745813808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03098-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3098"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03098-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to retrospective open access.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-025-03181-z","URL":"https:\/\/doi.org\/10.1007\/s12325-025-03181-z","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Piotr Wiland has served as a speaker and\/or advisory board member for AbbVie, AstraZeneca, Bristol Myers Squibb (BMS), Novartis, Pierre Fabre, Pfizer, Sandoz, Sobi, and UCB. Norman B. Gaylis has no conflicts of interest to declare. Charlotte Both was an employee of Hexal AG at the time of manuscript development and is a current employee of Gr\u00fcnenthal. Russell D. Cohen has served on the speakers\u2019 bureau for AbbVie, BMS\/Celgene, and Takeda; is a consultant for AbbVie, BMS\/Celgene, Eli Lilly and Company, Genentech, Gilead Sciences, Hoffmann La-Roche, Janssen, Pfizer, Takeda, and UCB Pharma; and is a clinical trials investigator for AbbVie, BMS\/Celgene, Boehringer Ingelheim, Crohn\u2019s & Colitis Foundation of America, Genentech, Gilead Sciences, Hollister, MedImmune, Mesoblast Ltd., Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. Jonas Halfvarson has served as a speaker and\/or advisory board member for AbbVie, Aqilion, BMS, Celgene, Celltrion, Dr Falk Pharma and the Falk Foundation, Ferring, Galapagos, Gilead, Hospira, Index Pharma, Janssen, MEDA, Medivir, Medtronic, MSD, Novartis, Pfizer, Prometheus Laboratories Inc., Sandoz, Shire, Takeda, Thermo Fisher Scientific, Tillotts Pharma, Vifor Pharma, and UCB; and has received grant support from Janssen, MSD, and Takeda. Lena Lemke was an employee of Hexal AG at the time of manuscript development. Oliver von Richter is an employee of Hexal AG. Andrew Blauvelt has served as a speaker (received honoraria) for AbbVie, Eli Lilly and Company, Pfizer, and UCB; has served as a scientific advisor (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB\u00a0Pharma, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}